SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas

Introduction: Prolactinomas are usually benign and respond well to dopamine agonist therapy. However, approximately 20% are resistant, and 10% behave aggressively and persist or recur. Treatment resistance has been associated with ErbB receptor expression, prompting us to conduct a trial of ErbB tar...

Full description

Saved in:
Bibliographic Details
Published in:J Endocr Soc
Main Authors: Cooper, Odelia, Bonert, Vivien, Rudnick, Jeremy, Pressman, Barry, Melmed, Shlomo
Format: Artigo
Language:Inglês
Published: Endocrine Society 2019
Subjects:
Neuroendocrinology and Pituitary
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553305/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-442
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items